A class of diabetes drugs already used by millions worldwide could be key to tackling Alzheimer’s disease, according to an emerging body of research. Scientists are increasingly focusing on GLP-1 receptor agonists, a group of medications designed to regulate blood sugar, as promising candidates for slowing or preventing the progression of the most common form of dementia. The findings were published in the journal Receptors.
These drugs, including dulaglutide, liraglutide, semaglutide, and exenatide, have long been used to treat type 2 diabetes and obesity. They work by mimicking a natural hormone that encourages insulin release and suppresses appetite. But researchers now believe they may also have profound effects on the brain.
A review published in January 2025 highlighted strong preclinical evidence suggesting these drugs can reduce the build-up of amyloid plaques and tau tangles in the brain—hallmarks of Alzheimer’s. They may also improve synaptic function and protect neurons from damage. Animal studies have shown cognitive improvements in treated subjects, with better memory retention and learning ability.
The rationale behind this approach stems from the growing understanding that Alzheimer’s and type 2 diabetes share several underlying mechanisms, including insulin resistance, inflammation, and oxidative stress. The idea that Alzheimer’s could be viewed as a form of “type 3 diabetes” is gaining traction in some scientific circles.
Although the findings from laboratory and animal studies are encouraging, translating this into effective treatment for humans remains a challenge. The blood-brain barrier, which protects the brain from harmful substances, can limit how much of the drug reaches the brain. There is also considerable variation in how individuals respond to treatment, and long-term effects in older adults are not yet fully understood.
Clinical trials are underway to explore these possibilities further. Early results from the REWIND trial showed dulaglutide was associated with a reduced risk of cognitive decline in people with type 2 diabetes. Other trials are focusing on semaglutide, with several large-scale studies examining its potential to slow memory loss in those with early Alzheimer’s. Liraglutide, another GLP-1 drug, has also shown promise in preserving brain structure and glucose metabolism in small human trials.
While not all studies have reported clear benefits, especially in more advanced stages of the disease, researchers remain hopeful. Many believe that GLP-1 drugs could be most effective when used before symptoms become severe.
If ongoing trials confirm their benefit, GLP-1 receptor agonists could reshape the landscape of dementia treatment. Their widespread availability and known safety profile in diabetes patients may offer a quicker path to approval compared to entirely new drugs. But experts caution that the road ahead still requires careful navigation, including addressing dosage, timing, and potential side effects in vulnerable populations.
